丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06872 丹诺医药-B

待上市 05-15 16:00:00

75.700

+0.000

0.00%

最高75.700	最低75.700	成交量0.00
今开75.700	昨收75.700	日振幅0.00%
总市值39.18亿	流通市值39.18亿	总股本5,175万
成交额0.00	换手率0.00%	流通股本5,175万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06872","market":"HK","secType":"STK","nameCN":"丹诺医药-B","latestPrice":75.7,"timestamp":1778832000000,"preClose":75.7,"halted":9,"volume":0,"delay":0,"changeRate":0,"floatShares":51753500,"shares":51753500,"eps":-3.417,"marketStatus":"待上市","change":0,"latestTime":"05-15 16:00:00","open":75.7,"high":75.7,"low":75.7,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.417,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779413400000},"marketStatusCode":8,"adr":0,"listingDate":1779379200000,"exchange":"SEHK","adjPreClose":75.7,"openAndCloseTimeList":[[1778808600000,1778817600000],[1778821200000,1778832000000]],"volumeRatio":0,"ipoDetail":{"name":"丹诺医药－B","exchange":"SEHK","listingDate":"2026-05-22","sharesOutstanding":51753476,"sharesFloat":51753476,"offerAmount":8280600,"priceRange":"75.700","market":"HK","openProspectusDate":"2026-05-14","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0514/2026051400014_c.pdf","purchaseBeginDate":"2026-05-14","purchaseEndDate":"2026-05-19","winningDate":"2026-05-21","currency":"HKD","minPurchaseQuantity":50,"peRate":-23.13,"use":"1、71.0%或约395.7百万港元将用于公司核心产品的研究、开发、注册备案及商业化；\n2、7.0%或约39.2百万港元，将用于为TNP-2092口服制剂的研发提供资金；\n3、7.3%或约40.9百万港元将用于研发公司的其他候选产品；\n4、7.2%或约40.2百万港元将用于建设公司自有工厂；\n5、7.5%或约41.8百万港元，将用作营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家临近商业化阶段的生物科技公司，专注于发现、开发及商业化差异化的创新药产品，以解决细菌感染及细菌代谢相关疾病领域的未被满足临床需求。","subscribed":80.83,"marketCap":3918000000,"minimumCapital":3823.17,"overAllotment":true,"lotSize":50,"issueOpenRate":0.1,"subscribeGear":"50,100,150,200,250,300,350,400,450,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,414050","issueRatio":0.1,"offeringMechanism":"B"},"greyMarketDetail":{"greyDate":"2026-05-21","greyDateTimestamp":1779292800000,"greyOpeningTime":1779351300000,"greyClosingTime":1779359400000,"showGreyQuote":false,"openProspectusDate":"2026-05-14","listingDate":"2026-05-22"},"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06872/tweets","defaultTab":"tweets","newsList":[{"id":"2635641085","title":"新股孖展统计 | 5月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635641085","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635641085?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:40","pubTimestamp":1778841628,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，驭势科技(01511)、拓璞数控(07688)结束招股，丹诺医药-B(06872)正在招股中。截至5月15日，富途证券、老虎国际等券商为驭势科技借出2258.72亿港元，超购逾5179.55倍；为拓璞数控借出4991.41亿港元，超购逾2894.08倍；为丹诺医药借出50.67亿港元，超购逾79.83倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07688","06872","IPOS","01511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635704654","title":"全球首创新药“硬实力”领跑，丹诺医药-B(06872)开启招股掘金抗感染赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2635704654","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635704654?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:30","pubTimestamp":1778833820,"startTime":"0","endTime":"0","summary":"5月6日，丹诺医药(苏州)股份有限公司顺利通过港交所主板上市聆讯，并已于5月14日正式开启招股，中信证券、农银国际担任联席保荐人。弗若斯特沙利文数据显示，幽门螺杆菌感染作为全球范围内的高发疾病，2024年全球治疗市场规模69亿美元，预计至2035年将攀升至161亿美元。在幽门螺杆菌感染治疗领域之外，丹诺医药在植入体相关细菌生物膜感染治疗方面同样取得了重要突破。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","159992","06978","BK1161","BK1574","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635727420","title":"严管药店销售司美格鲁肽、替尔泊肽等药品；丹诺医药今起招股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635727420","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635727420?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:01","pubTimestamp":1778803280,"startTime":"0","endTime":"0","summary":"政策导向严管药店销售司美格鲁肽、替尔泊肽等药品据公开资料，近日，江西省药品监督管理局发布《关于进一步加强司美格鲁肽、替尔泊肽等药品流通环节监督管理的通知》，针对在降糖及体重管理方面备受关注的司美格鲁肽、替尔泊肽等药品，强化流通环节监管，保障公众用药安全。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153738086145.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153738086145.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06872","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635716903","title":"新股孖展统计 | 5月14日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635716903","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635716903?lang=zh_cn&edition=full","pubTime":"2026-05-14 18:39","pubTimestamp":1778755191,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，驭势科技(01511)、拓璞数控(07688)、丹诺医药-B(06872)正在招股中。截至5月14日，富途证券、老虎国际等券商为驭势科技借出783.72亿港元，超购逾1796.53倍；为拓璞数控借出1804.35亿港元，超购逾1045.55倍；为丹诺医药借出12.23亿港元，超购逾18.51倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01511","06872","07688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635314718","title":"背负“对赌式”合作，丹诺医药赴港上市冲刺商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2635314718","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635314718?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:39","pubTimestamp":1778751576,"startTime":"0","endTime":"0","summary":"站在商业化的关键节点，丹诺医药正向港股发起冲刺。5月14日，丹诺医药（苏州）股份有限公司（以下简称“丹诺医药”）正式在港招股。财务数据显示，2023—2025年，该公司累计亏损近5亿元，经营活动现金流持续为负。截至2025年底，账上现金及现金等价物仅余1.84亿元。由于至今未实现盈利，丹诺医药长期依赖融资“输血”，2013年至今已通过7轮融资筹集超7亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143737538492.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737538492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635797018","title":"新股消息 | “幽门螺杆菌克星”丹诺医药(06872)招股火热","url":"https://stock-news.laohu8.com/highlight/detail?id=2635797018","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635797018?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:11","pubTimestamp":1778749903,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，被称为“幽门螺杆菌克星”的丹诺医药于2026年5月14日至5月19日招股。截至2026年5月4日，该公司已建立一条由七项创新项目组成的管线，包括两项核心产品，即：利福特尼唑，一款新分子实体候选药物，作为三联疗法的一部分与阿莫西林和质子泵抑制剂联合使用治疗幽门螺杆菌感染，亦作为单药疗法治疗细菌性阴道病及艰难梭菌感染;及利福喹酮，一款三靶点治疗植入体相关细菌感染的候选药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635335769","title":"丹诺医药-B于5月14日至5月19日招股 预计5月22日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2635335769","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635335769?lang=zh_cn&edition=full","pubTime":"2026-05-14 11:15","pubTimestamp":1778728555,"startTime":"0","endTime":"0","summary":"丹诺医药-B于2026年5月14日至5月19日招股，该公司拟全球发售828.055万股，其中香港发售占10%，国际发售占90%，发售价将为每股发售股份75.70港元，每手50股，预期股份将于2026年5月22日在联交所开始买卖。假设发售量调整权及超额配股权未获行使且基于发售价为每股75.70港元，公司估计将获得全球发售所得款项净额约5.578亿港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/14111557088733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IPOS","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635549807","title":"新股招股 | 丹诺医药今日至5月19日招股，一手入场费3823.17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635549807","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635549807?lang=zh_cn&edition=full","pubTime":"2026-05-14 07:18","pubTimestamp":1778714280,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B 于2026年5月14日至5月19日招股，该公司拟全球发售828.055万股，其中香港发售占10%，国际发售占90%，发售价将为每股发售股份75.70港元，每手50股，预期股份将于2026年5月22日在联交所开始买卖。假设发售量调整权及超额配股权未获行使且基于发售价为每股75.70港元，公司估计将获得全球发售所得款项净额约5.578亿港元。","market":"us","thumbnail":"https://static.tigerbbs.com/020a578f3bfe80c862f7fbdb142a7382","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/020a578f3bfe80c862f7fbdb142a7382"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3430ee0e05254278b5a3da84a7b77b4c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441472.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新股招股 | 丹诺医药今日至5月19日招股，一手入场费3823.17港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK1161","BK1574","06872","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1177879481","title":"丹诺医药（苏州）股份有限公司启动全球发售，每股定价75.70港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177879481","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177879481?lang=zh_cn&edition=full","pubTime":"2026-05-14 06:23","pubTimestamp":1778711036,"startTime":"0","endTime":"0","summary":"丹诺医药（苏州）股份有限公司主要从事抗菌药物的研发、生产及应用，针对幽门螺杆菌感染、手术相关感染以及耐药菌领域进行多元化布局，具有多重靶点偶联技术、新型复方抗菌制剂等核心技术。目前，公司在研产品正处于不同阶段的临床研究或商业化准备，涵盖口服制剂、注射制剂以及多项创新抗菌治疗方案，自主生产与管线拓展同步推进。发售前，公司单一最大股东集团Cumbre实体合计持股约18.82%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"丹诺医药（苏州）股份有限公司启动全球发售，每股定价75.70港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633981731","title":"新股消息 | 丹诺医药通过港交所聆讯 坐拥利福特尼唑(TNP-2198)和利福喹酮(TNP-2092)等核心产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2633981731","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633981731?lang=zh_cn&edition=full","pubTime":"2026-05-07 11:14","pubTimestamp":1778123674,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","BK1574","BK1161","159938","06872","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625384959","title":"丹诺医药二闯港交所，先进技术拥有者的危与机","url":"https://stock-news.laohu8.com/highlight/detail?id=2625384959","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625384959?lang=zh_cn&edition=full","pubTime":"2026-04-07 15:45","pubTimestamp":1775547917,"startTime":"0","endTime":"0","summary":"近日，被称为“幽门螺杆菌克星”的丹诺医药，第二次向港股发起冲刺。同时，其给药方案更为简便，有助于显著提升患者的治疗依从性。从成立至今，丹诺医药尚未有任何产品获准进行商业销售，也因此未能从产品销售中产生任何收入。截至2024年12月31日，丹诺医药的负债净额高达8.98亿元，呈现出明显的“资不抵债”状态。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775525752464364183","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","159938","06872","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617506306","title":"丹诺医药IPO：研发缩水三年亏3.76亿 合作背后暗藏对赌协议商业化前景仍存变数","url":"https://stock-news.laohu8.com/highlight/detail?id=2617506306","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617506306?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:39","pubTimestamp":1772764740,"startTime":"0","endTime":"0","summary":"　　在首次递表七个月后，丹诺医药（苏州）股份有限公司再次向港交所递交招股书，冲击主板上市。招股书显示，公司成立于2013年，专注于细菌感染与细菌代谢疾病领域，公司已与行业巨头远大生命科学达成潜在交易金额高达7.75亿元的商业化合作，背后还站着药明康德、北极光创投、高特佳投资等知名股东。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-03-06/doc-inhpzeqt9373365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1515","BK1574","159938","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614589607","title":"丹诺医药商业化突围战：研发投入下降，近8亿合作暗藏“对赌”","url":"https://stock-news.laohu8.com/highlight/detail?id=2614589607","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614589607?lang=zh_cn&edition=full","pubTime":"2026-02-28 08:20","pubTimestamp":1772238000,"startTime":"0","endTime":"0","summary":"　　2026年2月3日，专注于细菌感染及细菌代谢相关疾病领域的生物科技公司丹诺医药（苏州）有限公司向港交所递交招股书，拟在主板上市，中信证券与农银国际担任联合保荐人。然而，公司尚未实现产品商业化及收入突破，报告期内持续亏损且依赖外部融资，商业化进程中的多重风险亦不容忽视。　　尽管管线布局亮点突出，但丹诺医药目前尚未有产品获批商业化，未产生任何产品销售收入，报告期内持续录得净亏损。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-02-28/doc-inhpiryq3032705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","159938","06872","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610862026","title":"新股消息 | 丹诺医药港股IPO及境内未上市股份“全流通”获中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2610862026","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610862026?lang=zh_cn&edition=full","pubTime":"2026-02-09 14:17","pubTimestamp":1770617856,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月6日，中国证监会国际合作司发布《关于丹诺医药(苏州)股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司49名股东拟将所持合计43,472,926股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。利用这种独特的多靶点机制，利福特尼唑有望克服抗菌药物耐药性这一重要且日益严重的全球挑战。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159776","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609573727","title":"丹诺医药拿到IPO备案：暂无收入，9个月亏1.15亿 估值20亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2609573727","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609573727?lang=zh_cn&edition=full","pubTime":"2026-02-08 16:34","pubTimestamp":1770539667,"startTime":"0","endTime":"0","summary":"丹诺医药（苏州）股份有限公司（简称：“丹诺医药”）日前通过IPO备案，拿到了上市的钥匙。丹诺医药目前无收入，2025年前9个月亏损1.15亿。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260208/6390616523722649183398380.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260208/6390616523722649183398380.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32610/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK1161","159938","BK1515","BK1574","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609913323","title":"丹诺医药再冲港股：III期在手，资本会愿意这份确定性买单吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2609913323","media":"港股研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609913323?lang=zh_cn&edition=full","pubTime":"2026-02-05 14:22","pubTimestamp":1770272574,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/KL0RPE9G05317SYF.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/KL0RPE9G05317SYF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":0.02},{"period":"3month","weight":-0.0067},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1163},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"丹诺医药于2013年注册成立,是一家临近商业化阶段的生物科技公司,专注于发现、开发及商业化差异化的创新药产品,以解决细菌感染及细菌代谢相关疾病领域的未被满足临床需求。凭借自主开发的多靶点偶联分子技术,丹诺致力于为患者提供最佳治疗方案,以克服传统治疗的局限性并改善患者预后。截至2026年1月24日,丹诺已建立一条由七项创新项目组成的管线,包括两项核心产品,即:利福特尼唑(TNP-2198),一款新分子实体(“NME”)候选药物在中国及美国作为三联疗法的一部分与阿莫西林和PPI联合使用治疗幽门螺杆菌(“幽门螺杆菌”)感染,亦在中国作为单药疗法用于治疗细菌性阴道病及艰难梭菌感染;及利福喹酮(TNP-2092注射剂),一款三靶点治疗植入体相关细菌感染(如急性细菌性皮肤及皮肤结构感染(“ABSSSI”)及人工关节感染(“PJI”)以及在中国及美国治疗左心室辅助装置感染(“LVADI”)及中心静脉导管相关血流感染(“CRBSI”))的候选药物。","exchange":"SEHK","name":"丹诺医药-B","nameEN":"TENNOR THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丹诺医药-B,06872,丹诺医药-B股票,丹诺医药-B股票老虎,丹诺医药-B股票老虎国际,丹诺医药-B行情,丹诺医药-B股票行情,丹诺医药-B股价,丹诺医药-B股市,丹诺医药-B股票价格,丹诺医药-B股票交易,丹诺医药-B股票购买,丹诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}